Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company based in China and the United States. We are dedicated to discovering, developing, and commercializing best-in-class and first-in-class therapies that address medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease.
Guided by innovation and driven by purpose, our mission is to leverage our expertise and resources to take science out of the lab and into the lives of patients because every day matters in the fight against disease. Our long-term vision is to lead the next generation of biopharma by bringing innovative treatments to patients in need, bridging gaps in global health by advancing breakthrough therapies where they are needed most.
Founded in 2014 by Dr. Samantha Du, Zai Lab was purpose-built to become a leading global biopharma, combining scientific innovation, operational scale, and strong execution. Our global pipeline features zocilurtatug pelitecan (formerly known as ZL-1310), a DLL3-targeted antibody-drug conjugate (ADC) with best-in-class and first-in-class potential in small cell lung cancer, now in clinical trials. Our R&D team is also progressing several other global programs into the clinic, including ZL-1503, a bispecific IL-13/IL-31 antibody for atopic dermatitis, and ZL-6201, an LRRC15 ADC for solid tumors.
In China, we’ve earned a reputation as a partner of choice for leading global biopharmaceutical companies, leveraging our extensive commercial infrastructure and clinical trial capabilities to accelerate market success. Due to its large population, China is the second largest pharmaceutical market in the world. Our business model combines in-licensed assets with strategic partnerships, leveraging our in-house development capabilities to build a regional portfolio of late-stage, potential best-in-class and first-in-class therapies. Today, with eight products on the market in China, we are delivering meaningful impact for patients.
As a fully integrated biopharmaceutical company, we have the expertise and infrastructure to efficiently advance programs from early-stage discovery through development, approval, and commercialization. Our internal R&D centers focus on driving an innovative pipeline, supported by a strong clinical development team. These efforts are complemented by small-molecule and large-molecule manufacturing facilities, an experienced regulatory affairs group, and a highly specialized commercial organization. This end-to-end model provides Zai Lab and our partners with distinct advantages in a rapidly evolving global healthcare landscape.
Zai Lab’s global team includes industry leaders and professionals committed to accelerating breakthrough medicines. With headquarters in Cambridge, Massachusetts, and Shanghai, and teams in the U.S., Greater China, and Europe, we unite global expertise with local urgency to advance potential high-impact therapies to patients with few options.
